NCT03830606View on ClinicalTrials.gov

The Efficacy and Safety of Nab-paclitaxel Plus S-1 in First-line Treatment of Advanced Biliary Tract Adenocarcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

March 23, 2016

Primary Completion Date

September 2, 2018

Study Completion Date

September 1, 2019

Conditions
Biliary Tract Cancer
Interventions
DRUG

Nab-paclitaxel,S-1

Nab-paclitaxel 120 mg/m2 (D1, D8, q3w) and S-1 (40mg BID for body surface area \< 1.25 m2; 50mg BID for body surface area of 1.25-1.5 m2; and 60mg BID for body surface area \>1.5 m2; D1-14, q3w)

Trial Locations (1)

100021

National Cancer Center/Cancer Hospital, Chinese ACademy of Medical Sciences and Peking Union Medical College, Beijing

All Listed Sponsors
lead

Aiping Zhou

UNKNOWN

NCT03830606 - The Efficacy and Safety of Nab-paclitaxel Plus S-1 in First-line Treatment of Advanced Biliary Tract Adenocarcinoma | Biotech Hunter | Biotech Hunter